Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

CRL-40-941

This article is a stubmissing:
Interactions
Tolerance
Harm Potential
Legality
CRL-40-941 molecule structureCRL-40-941 molecule structure
Open in Piru
Chemical Class
Diphenylmethanethiol

CRL-40-941 is related to adrafinil and modafinil1. The patent describes its halogeno derivatives as psychotonic agents2. It is described as a tentative stimulant and nootropic with wakefulness-promoting effects, although its psychoactive class remains unknown. The compound is distinguished as adrafinil’s bis(4-fluoro) phenyl-ring derivative and was never marketed; it appears to have first been patented in the 1980s.

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~50 mg
Light50-100 mg
Moderate100-250 mg
Strong250+ mg
Heavy350+ mg

Duration

Onset30-90 minutes
After Effects1-10 hours
Total6-14 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Fladrafinil is used non-medically as a wakefulness-promoting agent and purported cognitive enhancer. The available material describes it only in these general terms and does not document the character or course of the subjective experience.

Physical

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → yellow2
Mecke(ME)
white → yellow2
Mandelin(MD)
yellow2 → brown2 → brown3
Liebermann(LB)
white → yellow2 → orange2
Powered by PROtestkit.eu

Pharmacology

Pharmacodynamics

Fladrafinil is a wakefulness-promoting agent related to modafinil. Modafinil and its analogues are known to act as dopamine reuptake inhibitors, and this is thought to be involved in their wakefulness-promoting effects. Fladrafinil has been found to produce antiaggressive effects in animals, which adrafinil does not produce, and is purportedly 3 to 4 times more potent than adrafinil in this action.

Pharmacokinetics

The pharmacokinetics of fladrafinil are being studied.

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Harm Potential not written up yet

History & Culture

4,4'-Difluorobenzhydrylsulfinylacetohydroxamic acid, designated Code No. CRL 40941 in the patent2, was never marketed. The compound appears in a patent family with a 1982 priority date and a U.S. publication in 19842 and is sold online for non-medical use as a nootropic.

Legality

Legality not written up yet

References

Citations

  1. Outsmarted by nootropics? An investigation into the thermal degradation of modafinil, modafinic acid, adrafinil, CRL-40,940 and CRL-40,941 in the GC injector: formation of 1,1,2,2-tetraphenylethane and its tetra fluoro analogue. Drug Testing and Analysis (2017). https://doi.org/10.1002/dta.21421
  2. Halogenobenzhydrylsulfinylacetohydroxamic acids. Google Patents (1984). https://patents.google.com/patent/US4489095A/en123

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the CRL-40-941 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.